{"filing":{"accession_number":"0001654954-26-008150","cik":"0000901832","ticker":"AZN","company_name":"ASTRAZENECA PLC","form":"6-K","filing_date":"2026-09-08","report_date":"2026-09-08","primary_document":"a5662t.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/901832/000165495426008150/a5662t.htm"},"events":[{"id":31740,"run_id":29142,"accession_number":"0001654954-26-008150","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This disclosure announces FDA approval of Etcamah (camizestrant) in combination with CDK4/6 inhibitors for first-line HR-positive breast cancer with emergent ESR1 mutations, based on positive Phase III SERENA-6 trial results showing 56% risk reduction in disease progression or death. While this is a significant regulatory and commercial milestone for AstraZeneca's oncology portfolio, it does not fit the specific event types of earnings_release, ma_activity, or other defined categories. It is a material operational/commercial event—a major product approval—that would affect investor assessment of the company's pipeline and market position, warranting operational_other classification.","company_name":"ASTRAZENECA PLC","ticker":"AZN","filing_date":"2026-09-08","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":34713,"accession_number":"0001654954-26-008150","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This disclosure announces FDA approval of Etcamah (camizestrant) in combination with CDK4/6 inhibitors for first-line HR-positive breast cancer with emergent ESR1 mutations, based on positive Phase III SERENA-6 trial results showing 56% risk reduction in disease progression or death. While this is a significant regulatory and commercial milestone for AstraZeneca's oncology portfolio, it does not fit the specific event types of earnings_release, ma_activity, or other defined categories. It is a material operational/commercial event—a major product approval—that would affect investor assessment of the company's pipeline and market position, warranting operational_other classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-08T10:30:20.262325+00:00","company_name":"ASTRAZENECA PLC","ticker":"AZN","filing_date":"2026-09-08"}]}